Epilepsy
Conditions
Interventions
Control group:None
Patient group:None
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.No age or gender restriction; 2.Patient group:Meets the diagnostic criteria for any of the listed diseases:Epilepsy; Parkinson's disease; Alzheimer's disease; mild cognitive impairment; dementia with Lewy bodies; frontotemporal dementia; major depressive disorder; schizophrenia; bipolar disorder; obsessive-compulsive disorder; trigeminal neuralgia; disorders of consciousness (e.g., coma, vegetative state, minimally conscious state); lesions involving functional brain areas (e.g., tumors, stroke, inflammation affecting motor, sensory, language, or visual areas). 3.The subject or their legal representative has been fully informed about the study and voluntarily signed the informed consent form; 4.Patients diagnosed at Nanfang Hospital, Southern Medical University, between September 2025 and August 2029; 5.Healthy control group:Frequency matching with the patient group will be conducted for age, gender, and years of education.
Exclusion criteria
Exclusion criteria: 1.Presence of metallic implants or magnetic foreign bodies contraindicated for OPM-MEG examination; 2.Pregnant or lactating women; 3.Other factors deemed unsuitable for participation in the study as determined by the investigator; 4.Patient group: Severe cognitive impairment or psychiatric symptoms leading to inability to cooperate with the study procedures (e.g., MoCA score <19 or deemed unable to follow instructions by the investigator); 5.Patient group: Severe claustrophobia preventing tolerance of head-mounted sensors or examination environment; 6.Patient group: Uncontrolled severe physical illnesses, including but not limited to severe cardiovascular diseases, liver or renal failure, malignant tumors (other than intracranial tumors targeted in the study), or active infections; 7.Patient group: Comorbid diagnoses of major neurological or psychiatric disorders outside the scope of the current research that may significantly impact brain function; 8.Patient group: Diagnosis of substance use disorders (e.g., alcohol, opioids, stimulants) according to DSM-5 criteria within the past 12 months; 9.Healthy control group: Does not meet the selection criteria for reference individuals as defined by "WS/T 402-2024 Reference Intervals for Clinical Laboratory Tests," or presence of any unhealthy conditions defined under neurological diseases; 10.Healthy control group: Has a first-degree family history of any diseases present in the patient group; 11.Healthy control group: Currently or within the past 6 months have regularly taken any medications that may affect the central nervous system (e.g., sedative-hypnotics, antidepressants/anxiolytics, psychostimulants, etc.); 12.Healthy control group: History of significant head trauma (defined as loss of consciousness lasting more than 5 minutes);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Original MEG Imaging Results; | — |
Countries
China
Contacts
Public ContactHao Long
Nanfang Hospital, Southern Medical University
Outcome results
None listed